Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 324 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obliterative Bronchiolitis Clear all
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 30, 2026, 6:01 PM EDT
Completed No phase listed Observational

Imaging and Understanding BOS in Lung Transplantation

NCT02316392
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Hyperpolarized Helium-3 MRI
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 30, 2026, 6:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

NCT00948519
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 30, 2026, 6:01 PM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 6:01 PM EDT
Active, not recruiting No phase listed Observational

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180
View directory record Official record
Conditions
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Interventions
Skin punch biopsy, Peripheral blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 6:01 PM EDT
Recruiting Not applicable Interventional

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT06299683
View directory record Official record
Conditions
Chronic Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Cystitis, Interstitial, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Psychosocial Treatment, Pelvic Floor Physical Therapy
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142
View directory record Official record
Conditions
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 30, 2026, 6:01 PM EDT
Terminated Not applicable Interventional

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

NCT02071979
View directory record Official record
Conditions
Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions
Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care
Device · Procedure
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
6
States / cities
Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Not applicable Interventional

TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)

NCT02413216
View directory record Official record
Conditions
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Interventions
TicHelper, Internet Based Resources
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
8 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Salt Lake City, Utah • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome

NCT01287078
View directory record Official record
Conditions
Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 4 Interventional

The Use of Cyproheptadine in Pediatric Feeding Disorders

NCT06751290
View directory record Official record
Conditions
Pediatric Feeding Disorder, Chronic, Avoidant Restrictive Food Intake Disorder
Interventions
Cyproheptadine, Nutritional Counseling, Behavioral Counseling
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
2 Years to 6 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

NCT00386334
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
82
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain Neuroscience Education for Depression

NCT04023435
View directory record Official record
Conditions
Chronic Low-back Pain, Depression
Interventions
PNE edcuation
Other
Lead sponsor
St. Ambrose University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 30, 2026, 6:01 PM EDT
Terminated Phase 4 Interventional Results available

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome

NCT00498485
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Placebo, Sodium Oxybate
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
21 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 30, 2026, 6:01 PM EDT
Recruiting Not applicable Interventional

MENTOR Wellness Program

NCT06148324
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
MENTOR Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 6:01 PM EDT
Completed Phase 2 Interventional

Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain

NCT00485225
View directory record Official record
Conditions
Chronic, Non Malignant Pain
Interventions
EN3270
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 30, 2026, 6:01 PM EDT